![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Lead Product(s): Nalfurafine
Therapeutic Area: Dermatology Product Name: TRK-820
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Immunis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 22, 2024